share_log

Needham Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $23

Needham Initiates Coverage On Neumora Therapeutics With Buy Rating, Announces Price Target of $23

Needham以買入評級覆蓋Neumora Therapeutics,宣佈目標股價爲23美元。
Benzinga ·  05:40  · 評級/大行評級

Needham analyst Ami Fadia initiates coverage on Neumora Therapeutics (NASDAQ:NMRA) with a Buy rating and announces Price Target of $23.

Needham分析師阿米·法迪亞開始對Neumora Therapeutics(納斯達克股票代碼:NMRA)進行報道,評級爲買入,並宣佈目標股價爲23美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論